2,5-DIFLUORO-4-CHLORO NICOTINIC ACID
- $45 - $155
- Product name: 2,5-DIFLUORO-4-CHLORO NICOTINIC ACID
- CAS: 851386-42-0
- MF: C6H2ClF2NO2
- MW: 193.54
- EINECS:
- MDL Number:MFCD09031177
- Synonyms:2,5-DIFLUORO-4-CHLORO NICOTINIC ACID;4-Chloro-2,5-difluoropyridine-3-carboxylic acid;3-Pyridinecarboxylic acid, 4-chloro-2,5-difluoro-
4 prices
Selected condition:
Brand
- Matrix Scientific
- TRC
Package
- 5mg
- 10mg
- 50mg
- 500mg
- ManufacturerMatrix Scientific
- Product number054388
- Product description4-Chloro-2,5-difluoropyridine-3-carboxylic acid 95%
- Packaging500mg
- Price$155
- Updated2021-12-16
- Buy
- ManufacturerTRC
- Product numberC585498
- Product description4-Chloro-2,5-difluoropyridine-3-carboxylicAcid
- Packaging5mg
- Price$45
- Updated2021-12-16
- Buy
- ManufacturerTRC
- Product numberC585498
- Product description4-Chloro-2,5-difluoropyridine-3-carboxylicAcid
- Packaging10mg
- Price$60
- Updated2021-12-16
- Buy
- ManufacturerTRC
- Product numberC585498
- Product description4-Chloro-2,5-difluoropyridine-3-carboxylicAcid
- Packaging50mg
- Price$90
- Updated2021-12-16
- Buy
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|
Matrix Scientific | 054388 | 4-Chloro-2,5-difluoropyridine-3-carboxylic acid 95% | 500mg | $155 | 2021-12-16 | Buy |
TRC | C585498 | 4-Chloro-2,5-difluoropyridine-3-carboxylicAcid | 5mg | $45 | 2021-12-16 | Buy |
TRC | C585498 | 4-Chloro-2,5-difluoropyridine-3-carboxylicAcid | 10mg | $60 | 2021-12-16 | Buy |
TRC | C585498 | 4-Chloro-2,5-difluoropyridine-3-carboxylicAcid | 50mg | $90 | 2021-12-16 | Buy |
Properties
Melting point :98-100 °C(Solv: chloroform (67-66-3); hexane (110-54-3))
Boiling point :284.8±35.0 °C(Predicted)
Density :1.674±0.06 g/cm3(Predicted)
pka :0.81±0.25(Predicted)
Boiling point :284.8±35.0 °C(Predicted)
Density :1.674±0.06 g/cm3(Predicted)
pka :0.81±0.25(Predicted)
Safety Information
Symbol(GHS): | ||||||||
---|---|---|---|---|---|---|---|---|
Signal word: | ||||||||
Hazard statements: |
|
|||||||
Precautionary statements: |
|